Hindustan Engineering & Industries Limited: What the Unlisted Shares Actually Look Like

​

Hindustan Engineering & Industries Limited (HEIL) isn't on the NSE or BSE, and that fact shapes almost everything else about this stock. Strip away the "unlisted" label for a moment, though, and you're looking at a genuinely established engineering business sitting inside India's railway and industrial supply chain: bogies, couplers, draft gears, crossings, freight wagons, steel castings, plus smaller chemicals and jute operations on the side.

 At the indicative price of ₹1,050 a share, the market is putting a ₹1,544.21 crore tag on a company that pulled in ₹218.36 crore in profit after tax. Run the numbers and you land on a P/E of about 7.07x — cheap for a profitable industrial name and a P/B of 1.03x, so the stock is trading just above book value.

 That's the appealing part. The less appealing part is liquidity. Unlisted shares don't trade on an exchange, and there's no guarantee you'll find a buyer the day you decide to sell. That risk sits underneath every number in this report, and it's worth keeping in mind before anything else.

 What the Company actually does

 HEIL's business is built around engineering and manufacturing, and railways make up a meaningful chunk of it. The company produces rolling-stock components — freight wagons, bogies, side frames, bolsters, couplers, draft gears along with railway track products like crossings. Its steel foundry operations matter here too, since a lot of railway components need specialised casting work that not every manufacturer can do in-house.

 Beyond railways, HEIL also has some exposure to chemicals and jute. That's not a bad thing: a business that isn't leaning on one product line for all its revenue tends to be a bit more resilient. The trade-off is that HEIL won't get valued the way a pure-play railway supplier might; the market tends to reward focus, even when diversification is arguably the smarter long-term bet.

 # The Numbers Here's what the research shows:

At ₹1,050, you're paying roughly seven times earnings. The share price sits only a touch above the reported book value of ₹1,022.78, too.

 Flip the P/E around and you get an earnings yield of 14.14%. Put simply: the company's reported profit works out to about 14% of what you'd pay for the stock today. That's a useful sanity check on the valuation even for people who don't think in P/E multiples.

 # Growth Doesn't Look Like a Fluke

 The historical numbers are arguably the best part of the HEIL story.

 Sales growth, compounded:

 - 1-year: 7.32% 

- 3-year: 45.54% 

- 5-year: 29.25%

 Profit growth, compounded  and this is the more interesting one:

 - 1-year: 5.35%

 - 3-year: 77.97%

 - 5-year: 58.72%

 Notice the gap. Profits have grown a lot faster than sales, which usually means margins are improving rather than the company just doing more volume at the same profitability. That's generally the more sustainable kind of growth.

 Return on equity backs this up:

 - 2021: 3.73%

 - 2023: 5.98%

 - 2025: 14.52% 

14.52% isn't a spectacular ROE by industrial-sector standards, but going from under 4% to over 14% in four years is a real shift in how efficiently the company is using shareholder capital — not just a one-off good year. The EPS of ₹148.48 is consistent with that story.

 Is the Profit Real Cash, or Just Paper? 

For an engineering company, profit on paper and cash in the bank can drift apart pretty easily. Big orders eat up working capital, and receivables can climb faster than earnings if customers are slow to pay. 

So it matters that cash flow from operations came in at ₹184.50 crore against ₹218.36 crore of PAT. That's a healthy proportion, and it suggests the reported profit isn't just an accounting construct — there's real cash backing most of it.

 That said, this is one number worth watching over time rather than taking as settled. Engineering and railway contracts can swing working capital around depending on execution timelines and how quickly customers pay, so a good year on this front doesn't guarantee the next one looks the same

 # The Railway Angle

 Railways are probably the single biggest structural story behind HEIL, for better or worse. India keeps pouring money into rail infrastructure, freight capacity, rolling stock and modernisation, and rising freight volumes create ongoing demand for wagons and specialised components. HEIL's track record in this space — components, rolling stock, the works — gives it a real foothold, not a speculative one. It’s also not a single-product bet. The company touches railway track materials and specialised components too, which means it participates in more than one leg of the railway capex cycle.

 # Valuation: The Part That Looks Cheapest

 If there's one clean argument for HEIL, it's the price.

 At ₹1,050 and an EPS of ₹148.48, the P/E works out to about 7.07x. The P/B, based on a book value of ₹1,022.78, comes in at 1.03x. For a company clearing ₹200+ crore in annual profit, that's not an expensive-looking stock on paper.

 The  reports also flags an intrinsic value of ₹13,518.66 per share — a huge gap from the current indicative price. Worth being careful here: intrinsic value estimates depend heavily on the assumptions baked into the model — growth rates, margins, discount rate, terminal value — and small changes to any of those inputs can move the number a lot. Treat it as a reference point from one particular model, not a target price you're owed.

Some of the discount in the current price is probably just the unlisted-status tax. No continuous exchange trading means no guarantee you can exit at the quoted price whenever you want to, and the market prices that uncertainty in.

 # How the Price Has Actually Move

 Stock-price CAGR 

- 1-year: -28.57%

 - 2-year: 0%

 - 3-year: 69.4%

 Read these differently than you'd read a listed stock's returns. Unlisted shares change hands through negotiated deals between a relatively small pool of buyers and sellers, not continuous exchange trading, so the price can swing hard based on who happens to be looking to buy or sell at a given moment — regardless of what's actually happening at the company.

 Which means: even if HEIL's fundamentals keep improving, don't expect the price to track that improvement smoothly or immediately.

 # What's Working in HEIL's Favor

 Cheap on the numbers. A 7.07x P/E and 1.03x P/B is a low entry point by most industrial-sector standards.

 Profit growth that's actually accelerating. 77.97% over three years and 58.72% over five years. That's not a rounding error, it's a real trend.

 A real railway footprint. India's ongoing rail infrastructure spending is a tailwind HEIL is positioned to benefit from, assuming execution holds up.

 Capital efficiency is improving. ROE nearly quadrupled from 3.73% in 2021 to 14.52% in 2025.

 The profit looks like real cash. ₹184.50 crore of operating cash flow against ₹218.36 crore PAT is a solid ratio.

 More than one leg to stand on. Steel castings, chemicals and jute mean HEIL isn't purely a railway bet.

 # What Could Go Wrong 

Liquidity, above everything else. Being unlisted means finding a buyer when you want to sell isn't guaranteed — this is the risk that overshadows all the others.

 Don't buy this expecting an IPO. There's no announced listing process. Treating an eventual IPO as the thesis is a bet on something that may never happen.

Orders won orders executed well. Delays, cost overruns, or margin slippage on railway and engineering contracts can eat into profitability even when the order book looks strong.

 Working capital can bite. Large industrial orders tie up cash in inventory and receivables profit on the income statement needs to keep showing up as cash, not just as a number.

 Steel prices are out of HEIL's control. If input costs rise and can't be passed on to customers, margins take the hit.

 The ₹13,518.66 intrinsic value isn't a promise. It's model output, sensitive to assumptions. Don't treat the gap between that number and the current price as upside you're entitled to.

 Put it together and HEIL looks like a company with improving fundamentals, a real railway footprint, and a valuation that's genuinely low on the numbers. ₹2,956.86 crore of total income turned into ₹218.36 crore of PAT, EPS of ₹148.48, and a share price that only costs you about 7.07x that — with the stock sitting barely above book value at 1.03x.

 The trend lines back this up. Five-year sales growth of 29.25%, five-year profit growth of 58.72%, ROE climbing from 3.73% to 14.52%, and ₹184.50 crore of operating cash flow behind the reported profit. On paper, this isn't a story of a company inflating its numbers the growth looks earned.

 Liquidity is the catch, and it's a real one. Anyone buying into HEIL needs to be comfortable holding an unlisted stock for a long stretch, with no assumption that an exit will be available on demand or at a price they like.

 So  fundamentals look positive, valuation looks attractive, growth is moderate-to-strong, profitability is improving, cash-flow quality is reasonably solid  and liquidity risk is high enough that it deserves to be treated as the deciding factor, not a footnote. An IPO isn't something to bank on. 

​